NCT07517432 The UGIRA International Registry for RAMIG for Gastric Cancer
| NCT ID | NCT07517432 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Gastric Cancer (Diagnosis) |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2021-04-01 |
| Primary Completion | 2031-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2021-04-01 with a primary completion date of 2031-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Minimally invasive gastrectomy (MIG) has gained in popularity, since it is feasible, safe and oncologically comparable to open gastrectomy, while morbidity and duration of hospitalization are reduced, quality of life is increased, and conversion rate is low. However, several challenges are faced during MIG, such as impaired depth perception and limited range of motion of instrument tips. Robot-Assisted Minimally Invasive Gastrectomy (RAMIG) can potentially overcome these challenges, while providing comparable results regarding safety, technical feasibility, morbidity and oncological effectiveness. However, the techniques and outcomes of RAMIG vary in literature, which can partly be explained by lack of uniform definitions of postoperative outcomes that would allow international comparison. Furthermore, RAMIG is technically demanding and therefore associated with a learning curve. To facilitate safe and effective implementation of RAMIG worldwide, the learning curve for RAMIG-procedures must be evaluated in detail. A prospective international registry with uniform data collection regarding surgical techniques and postoperative outcomes can provide a platform for multicontinental studies and the monitoring of surgical quality for surgeons who are implementing RAMIG in their center. Therefore, the aim of this study proposal is to expand the Upper Gastrointestinal International Robotic Association (UGIRA) collaboration by creating the UGIRA International Registry for RAMIG. The UGIRA network extends worldwide with members in Europe, Asia, North-America and South-America, therefore representing large-scale practice of RAMIG. The initial specific aims of the registry are to gain insight in surgical techniques and postoperative outcomes of RAMIG worldwide, and to evaluate the learning curve for RAMIG. Data for this registry is collected prospectively and retrospectively.
Eligibility Criteria
Inclusion Criteria: * All gastric cancer patients undergoing RAMIG in a center Exclusion Criteria: * No
Contact & Investigator
Shannon Melissa CHAN, MBChB, FRCSEd, FHKAM (Surgery)
✉ shannonchan@surgery.cuhk.edu.hk📞 +852 3505 2956
Shannon Melissa CHAN, MBChB, FRCSEd, FHKAM (Surgery)
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT07517432 clinical trial?
This trial is open to participants of all sexes, studying Gastric Cancer (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07517432 currently recruiting?
Yes, NCT07517432 is actively recruiting participants. Contact the research team at shannonchan@surgery.cuhk.edu.hk for enrollment information.
Where is the NCT07517432 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT07517432 clinical trial?
NCT07517432 is sponsored by Chinese University of Hong Kong. The principal investigator is Shannon Melissa CHAN, MBChB, FRCSEd, FHKAM (Surgery) at Chinese University of Hong Kong. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.